CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
2021 · Nature Medicine · 545 citations
https://doi.org/10.1038/s41591-021-01436-0
J
Jay Y. Spiegel
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
107
Papers
3.5K
Citations
25
h-index
36
i10-index
Jay Y. Spiegel is an academic researcher from Hackensack University Medical Center. The author has contributed to research in topics: CAR-T cell therapy research & Muscle Physiology and Disorders & Viral Infectious Diseases and Gene Expression in Insects. The author has an h-index of 25, co-authored 91 publications.
ORCID: 0000-0001-6491-0044Papers by this author
worksImmune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
2021 · Blood Advances · 179 citations
https://doi.org/10.1182/bloodadvances.2020002732
Engineered CD47 protects T cells for enhanced antitumour immunity
2024 · Nature · 101 citations
https://doi.org/10.1038/s41586-024-07443-8
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
2024 · The Lancet · 47 citations
https://doi.org/10.1016/s0140-6736(24)00746-3
Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium
2021 · Blood · 6 citations
https://doi.org/10.1182/blood-2021-147488
Donor Organ-Induced Thrombotic Microangiopathy in Kidney Transplant Recipients: A Novel Process or Better Understanding of an Old Problem?
2025 · American Journal of Transplantation · 0 citations
https://doi.org/10.1016/j.ajt.2025.07.2213
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat